santina battaglia

Dr. santina battaglia

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
MRMariangela Rondanelli
Mariangela Rondanelli
CGClara Gasparri
Clara Gasparri
GBGaetan Claude Barrile
Gaetan Claude Barrile
SBsantina battaglia
santina battaglia
ACAlessandro Cavioni
Alessandro Cavioni
SPSimone Perna
Simone Perna
Sarcopenia is a complex process characterized by a progressive decrease in muscle mass and strength. Various nutrients have been shown to be effective in supporting muscular performance. This randomized clinical trial aimed to evaluate the effectiveness of a 2-month administration of food for special medical purposes composed of omega-3 fatty acids (500 mg), leucine (2.5 g), and probiotic Lactobacillus paracasei PS23 (LPPS23), on appendicular lean mass (ALM), muscle performance, inflammatory status, and amino acid profile in sarcopenic patients. A total of 60 participants (aged 79.7 ± 4.8 years and a body mass index of 22.2 ± 2.1 kg/m2) were enrolled and randomly assigned to either intervention (n = 22) or placebo group (n = 28). Comparing the differences in effects between groups (intervention minus placebo effects), ALM increased significantly in the intervention group (p < 0.05), with no discernible change in the placebo group. Similarly, significant differences were also observed for the Tinetti scale (+2.39 points, p < 0.05), the SPPB total score (+2.22 points, p < 0.05), and the handgrip strength (4.09 kg, p < 0.05). Visceral adipose tissue significantly decreased in the intervention group compared to the placebo group at 60 days −0.69 g (95% CI: −1.09, 0.29) vs. 0.27 g (95% CI: −0.11, 0.65), groups difference −0.96 (95% CI: −1.52, 0.39, p = 0.001). A statistically significant increase in levels of valine, leucine, isoleucine, and total amino acid profiles was observed in the intervention group compared with the placebo group at 60 days (p = 0.001). When taken together, these beneficial effects may be attributed to the innovative composition of this special medical-purpose food which could be considered for the treatment of sarcopenia in the elderly.

Verified
Journal Article
Open access
PDF file
Teresa GriecoTeresa Grieco
Teresa Grieco
Giovanni PaolinoGiovanni Paolino
Giovanni Paolino
EMElisa Moliterni
Elisa Moliterni
CCCamilla Chello
Camilla Chello
ASAlvise Sernicola
Alvise Sernicola
SCStefano Calvieri
Stefano Calvieri
Vitamin D is increasingly recognized as a key regulator of epithelial barrier integrity and mucosal immune homeostasis, with implications extending far beyond skeletal health. Through the vitamin D receptor (VDR), vitamin D regulates epithelial cohesion, innate immune responses, and tight-junction gene expression. This review explores the multifactorial role of vitamin D in modulating inflammation and preserving tissue barriers, with particular emphasis on its effects on tight junction (TJ) regulation and disease states characterized by barrier dysfunction, namely atopic dermatitis, psoriasis, inflammatory bowel disease (IBD), and celiac disease. In these settings, vitamin D/VDR signaling exerts protective actions by enhancing barrier structure, suppressing Th1/Th17-driven inflammation, modulating the gut and skin microbiome, and promoting epithelial repair. Animal studies and clinical data suggest that vitamin D supplementation can restore TJ expression, reduce disease activity, and improve clinical outcomes in both intestinal and dermatologic diseases. In the cardiovascular system, the role of vitamin D remains complex. While vitamin D influences endothelial function, insulin sensitivity, and systemic inflammation, supplementation trials yield mixed results, indicating a need for individualized approaches. Overall, this review synthesizes mechanistic, translational, and clinical data supporting vitamin D as a crucial modulator of barrier integrity and inflammation. These findings highlight its therapeutic relevance in chronic diseases characterized by immune dysregulation and epithelial disruption.

Verified
Journal Article
Open access
PDF file
Teresa GriecoTeresa Grieco
Teresa Grieco
Giovanni PaolinoGiovanni Paolino
Giovanni Paolino
EMElisa Moliterni
Elisa Moliterni
CCCamilla Chello
Camilla Chello
ASAlvise Sernicola
Alvise Sernicola
SCStefano Calvieri
Stefano Calvieri
Atopic dermatitis (AD) is a chronic inflammatory skin disorder influenced by proteins involved in skin barrier maintenance and vitamin D metabolism. Using an intra-patient design, this study compared protein expression in intra-lesional (IL) and peri-lesional (PL) skin biopsies from AD patients and examined associations between protein levels, vitamin D status, and clinical features. Forty-four biopsies from twenty-two AD patients were analyzed using antibody microarrays targeting twelve proteins. IL samples had significantly higher total protein levels than PL samples, with a mean difference of 77.7% (p < 0.001). Several proteins, including cathelicidin, cingulin, occludin, filaggrin, and the vitamin D receptor, were upregulated in IL samples. Patients with vitamin D levels below 30 ng/mL showed higher expression of CYP24A (p = 0.054), alpha-catenin (p = 0.043), and haptoglobin (p = 0.033). Increased EASI scores (≥16) were associated with elevated expression of CYP24A (p = 0.024), CYP27B (p = 0.044), filaggrin (p = 0.027), occludin (p = 0.049), and claudin-1 (p = 0.052). Multivariate regression analysis identified significant correlations between protein expression, skin prick test positivity, and low vitamin D levels. These findings suggest that proteins related to epithelial barrier function and vitamin D metabolism are highly upregulated in IL skin regions, offering potential therapeutic targets for improving both skin barrier function and overall disease severity in AD patients.

Verified
Journal Article
Open access
PDF file
Teresa GriecoTeresa Grieco
Teresa Grieco
Giovanni PaolinoGiovanni Paolino
Giovanni Paolino
EMElisa Moliterni
Elisa Moliterni
CCCamilla Chello
Camilla Chello
ASAlvise Sernicola
Alvise Sernicola
SCStefano Calvieri
Stefano Calvieri
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by impaired barrier function and immune dysregulation. This study explores transcriptomic differences between lesional (IL) and perilesional (PL) skin in patients with AD, focusing on barrier-related and vitamin D-associated pathways. RNA sequencing was performed on matched IL and PL biopsies from 21 adults with moderate-to-severe AD. Differential gene expression, pathway enrichment, and correlation analysis with clinical variables were assessed. A total of 8817 genes were differentially expressed in IL versus PL skin (padj < 0.05). Among genes with the highest level of dysregulation, strong upregulation was observed for inflammatory mediators (IL-19, IL-8, CXCL6), and epidermal remodeling and barrier-disrupting genes (MMP1, GJB2). The vitamin D pathway genes CYP27B1 and CYP24A1 were also significantly upregulated. In contrast, key barrier-related genes such as FLG2 and CGNL1 were markedly downregulated. While some patterns in gene expression showed subgroup-specific trends, no independent clinical predictors emerged in multivariate models. Reactome pathway analysis revealed the enrichment of pathways involved in keratinization, cornified envelope formation, IL-4/IL-13 signaling, chemokine activity, and antimicrobial responses, highlighting coordinated structural and immunologic dysregulation in lesional skin. Lesional skin in AD displays a distinct transcriptomic profile marked by barrier impairment, heightened inflammatory signaling, and activation of vitamin D-related pathways. These findings provide the first RNA-seq-based comparison of IL and adjacent PL skin in AD. We identify subclinical activation in PL skin and vitamin D pathway upregulation with disrupted gene coordination in lesions. These findings enhance our understanding of the molecular mechanisms underlying inflammation in AD.

27 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Teresa GriecoTeresa Grieco
Teresa Grieco
Giovanni PaolinoGiovanni Paolino
Giovanni Paolino
EMElisa Moliterni
Elisa Moliterni
CCCamilla Chello
Camilla Chello
ASAlvise Sernicola
Alvise Sernicola
SCStefano Calvieri
Stefano Calvieri
Atopic dermatitis (AD) is a chronic inflammatory skin disorder influenced by proteins involved in skin barrier maintenance and vitamin D metabolism. This study compares protein expression in intra-lesional (IL) and peri-lesional (PL) skin biopsies from AD patients and examines associations between protein levels, vitamin D status, and clinical features. Forty-four biopsies from 22 AD patients were analyzed using antibody microarrays targeting 12 proteins. IL samples had significantly higher total protein levels than PL samples, with a mean difference of 77.7% (p<0.001). Several proteins, including cathelicidin, cingulin, occludin, filaggrin, and the vitamin D receptor, were upregulated in IL samples. Patients with vitamin D levels below 30 ng/ml showed higher expression of CYP24A (p=0.054), alpha-catenin (p=0.043), and haptoglobin (p=0.033). Increased EASI scores (≥16) were associated with elevated expression of CYP24A (p=0.024), CYP27B (p=0.044), filaggrin (p=0.027), occludin (p=0.049), and claudin-1 (p=0.052). Multivariate regression analysis identified significant correlations between protein expression, skin prick test (SPT) positivity, and low vitamin D levels. These findings suggest that proteins related to epithelial barrier function and vitamin D metabolism are highly upregulated in IL skin regions, offering potential therapeutic targets for improving both skin barrier function and overall disease severity in AD patients.

22 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Teresa GriecoTeresa Grieco
Teresa Grieco
Giovanni PaolinoGiovanni Paolino
Giovanni Paolino
EMElisa Moliterni
Elisa Moliterni
CCCamilla Chello
Camilla Chello
ASAlvise Sernicola
Alvise Sernicola
SCStefano Calvieri
Stefano Calvieri
Vitamin D is increasingly recognized as a key regulator of epithelial barrier integrity and mucosal immune homeostasis, with implications extending far beyond skeletal health. This review explores the multifactorial role of vitamin D in modulating inflammation and preserving tissue barriers, with particular emphasis on its effects on tight junction (TJ) regulation and disease states characterized by barrier dysfunction. Acting through the vitamin D receptor (VDR), vitamin D influences epithelial cohesion, innate immune re-sponses, and gene expression relevant to TJ. We critically examine current evidence linking vitamin D deficiency with chronic in-flammatory conditions in which epithelial barrier impairment is central—namely atopic dermatitis, psoriasis, inflammatory bowel disease (IBD), and celiac disease. In these set-tings, vitamin D/VDR signaling exerts protective actions by enhancing barrier structure, suppressing Th1/Th17-driven inflammation, modulating the gut and skin microbiome, and promoting epithelial repair. Animal studies and clinical data suggest that vitamin D supplementation can re-store TJ expression, reduce disease activity, and improve clinical outcomes in both intes-tinal and dermatologic diseases. In the cardiovascular system, its role remains complex: while vitamin D influences endothelial function, insulin sensitivity, and systemic inflammation, supplementation trials yield mixed results, indicating a need for individualized approaches. Overall, this review synthesizes mechanistic, translational, and clinical data sup-porting vitamin D as a crucial modulator of barrier integrity and inflammation. These findings highlight its therapeutic relevance in chronic diseases characterized by immune dysregulation and epithelial disruption.